Scholarlink

<p>The AKT1 (E17K) mutation, associated wit<!--Query ID="Q1" Text="Please note that email id (Jiapengxue@taihehospital) is not valid, Kindly provide the valid e-mail id to proceed further or amend if necessary" Resolved="yes"-->h unfavourable outcomes in solid tumours, promotes cancer proliferation and persistence. A recent study by Gregory et al. discovered a reversible covalent inhibitor targeting this mutation, exhibiting significant anti-tumor action with little effects on normal cells. This advancement provides a targeted therapeutic approach for AKT-mutant malignancies and informs further inhibitor research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Selective targeting of the AKT1 (E17K) mutation: advances in precision oncology and therapeutic design

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月3日

查看全文
  • Xiaoyan Chen,
  • Danfeng Zhang,
  • Jiapeng Xue,
  • Zhi Li

摘要

The AKT1 (E17K) mutation, associated with unfavourable outcomes in solid tumours, promotes cancer proliferation and persistence. A recent study by Gregory et al. discovered a reversible covalent inhibitor targeting this mutation, exhibiting significant anti-tumor action with little effects on normal cells. This advancement provides a targeted therapeutic approach for AKT-mutant malignancies and informs further inhibitor research.